BLAINJECTIONINJECTABLE1 Generic Approved
Approved
Oct 2023
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
COSENTYX (secukinumab) by Novartis is interleukin-17a antagonists [moa]. Approved for interleukin-17a antagonist [epc]. First approved in 2023.
Drug data last refreshed 21h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
COSENTYX (secukinumab) is a monoclonal antibody that selectively blocks interleukin-17A (IL-17A), a key cytokine driving inflammatory and autoimmune diseases. It is used to treat conditions including plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and other IL-17A-mediated disorders. By inhibiting IL-17A signaling, secukinumab reduces inflammation and improves clinical outcomes across multiple indication areas.
Growth
COSENTYX is in active growth phase with moderate competitive pressure (30%), indicating expanding team headcount and investment in commercial infrastructure.
Mechanism of Action
Interleukin-17A Antagonists
Pharmacologic Class:
Interleukin-17A Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Study of Early Secukinumab Treatment in Moderate to Severe Hidradenitis Suppurativa Patients
Started Oct 2026
186 enrolled
Hidradenitis Suppurativa
A Study to Assess the Safety of Subcutaneous Secukinumab for Treatment in Adult Indian Participants With Axial Spondyloarthritis (axSpA), Ankylosing Spondylitis (AS), and Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
Started Sep 2026
60 enrolled
Axial SpondyloarthritisAnkylosing SpondylitisNon-Radiographic Axial Spondyloarthritis
A Real-world Study of Patients With Hidradenitis Suppurativa and High Cardiovascular Risk or Established Coronary Plaque Treated With Secukinumab
Started Jul 2026
34 enrolled
Hidradenitis Suppurativa
A Study to Estimate Secukinumab Retention Rate in Psoriasis Patients With MASLD
Started Jul 2026
150 enrolled
Plaque PsoriasisMetabolic Dysfunction-Associated Steatotic Liver Disease
Metformin Combined With Secukinumab for Moderate-to-Severe Plaque Psoriasis in Overweight or Obese Chinese Patients
Started Jun 2026
186 enrolled
PsoriasisPlaque PsoriasisModerate-to-severe Plaque Psoriasis+1 more
Worked on COSENTYX at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.